Most previous studies that have exam-ined the survival of patients with parkinsonism have recruited them from specialist centres. No previous study has ever reported cause specific mortality. We report on the mortality of a cohort of 220 parkinsonian patients recruited between 1970 and 1972 from 40 primary health care practices all over England and Wales and matched to 421 controls. At 20 years of follow up, 195 cases (88-6%) and 295 controls (70.1%) were no longer alive (P < 0.001). The median age at death for cases was 77-6 (range 53-8-97-3) and 83'5 (range 55.0-100.1) for controls (P < 0.001). The all cause hazard ratio for cases compared with controls was 2-6 (95% confidence interval (95% CI) 2.2-3.2) controlling for age, sex, and geographical region. There was little difference between men and women. Differences for cause specific mortality also emerged. Both ischaemic heart disease (2.3, 95% CI 1.5-3.4) and cerebrovascular disease (3'6, 95% CI 2.2-6.1) showed significantly increased hazard ratios. Possible reasons for these findings are discussed in terms of (a) competing causes of death, (b) a secondary effect of drug treatment, and (c) common aetiological factors for both parkinsonism and cardiovascular disease. (7 Neurol Neurosurg Psychiatry 1995;58:293-299) Keywords: Parkinson's disease; aetiology controls and may have underestimated the relative mortality as such controls are more likely to have other serious diseases. Almost all of these studies have recruited their cases from specialist neurology units. This is problematic as specialist units may, in general, recruit more atypical and severe cases of neurological diseases.'7 Only one study has been based on the follow up of a representative population based sample.'6 This study importantly reported that parkinsonian cases had a 2*5-fold greater relative risk of dying than the general population, similar and only slightly improved on the relative mortality seen for the prelevodopa era.4 This result was based on follow up for only a 3-5 year period.
controls and may have underestimated the relative mortality as such controls are more likely to have other serious diseases. Almost all of these studies have recruited their cases from specialist neurology units. This is problematic as specialist units may, in general, recruit more atypical and severe cases of neurological diseases.'7 Only one study has been based on the follow up of a representative population based sample. '6 This study importantly reported that parkinsonian cases had a 2*5-fold greater relative risk of dying than the general population, similar and only slightly improved on the relative mortality seen for the prelevodopa era.4 This result was based on follow up for only a 3-5 year period.
Cause of death among parkinsonian patients may provide a useful insight into aetiology. If they are also more likely to die of another disease, there may be a common genetic or environmental link between these disorders. No previous study has ever examined cause specific mortality of Parkinsonian cases compared with the general population.
We have examined both total and cause specific mortalities of a cohort of parkinsonian cases and matched population based controls recruited from primary health care facilities followed up for a 20 year period. This avoids previous methodological problems concerning ascertainment bias and the choice of an appropriate comparative group. Our aims were (a) to determine whether the mortality of parkinsonian cases had improved since the introduction of levodopa; (b) to determine whether any possible clue to the aetiology of parkinsonism might be found if these cases were more or less likely to die of other diseases.
The introduction of levodopa treatment in the late 1960s had a clear and dramatic effect on the symptoms of patients with Parkinson's disease. Unfortunately no randomised placebo controlled trial was ever established. It is generally assumed that the introduction of levodopa treatment has improved the relative mortality for parkinsonian cases compared with the rest of the population. Most previous research has either been based on case series without healthy control data' 2 or has used comparative routine mortality statistiCS.3-14 All but two of these studies used national mortality, which may not be appropriate due to variations in regional mortality. Two studies have compared the mortality of parkinsonian cases with relevant matched controls.'5 16 (See table 1 for a summary of other studies.) One of these'5 used hospital Subjects and methods The cohort of parkinsonian cases and controls was derived from 64 general practices throughout England and Wales that took part in the Second National Morbidity study. 18 The diagnoses for all patient episodes were recorded for a one year period. All subjects were recruited into the cohort between 25 November 1970 and 23 November 1972. In 1981, the computerised records were used to identify all patients with a diagnostic code of Parkinson's disease. Two controls were randomly selected from the register of the same practice and matched by sex and same year of birth. The NHS numbers of all subjects were sent to the National Health Service Central Register to determine vital status. All deaths were subsequently informed to us by flagging Results Four hundred and sixty parkinsonian patients in 64 practices were initially identified through the computerised records. To enable flagging, it was necessary for us to obtain personal details on the subjects from their general practitioner. Two hundred and forty patients were not entered because (a) the general practitioner had either died or moved (65 cases); (b) the general practitioner refused or failed to respond (76 cases); (c) insufficient information was provided on the patient to enable flagging (99 cases). We were therefore left with 220 cases from 40 practices and 421 matched controls. It was not always possible to generate two controls for every case, because of difficulties with flagging. There was no difference in age and sex between subjects that did and did not enter the study.
The median age at entry of the 220 patients was 69-3 (range 32 9-90 7) and of the 421 matched controls 69-5 (range 31 5-89-7) and there was no difference in the age distribution. There were more women than men: 57-7% for cases and 59-4% for controls. The regional distribution of subjects was as follows: southern England (42-3% cases, 41-9% controls), midlands (10-0% cases, 12-3% controls), northern England (41-9% cases, 39-2% controls), and Wales (5 9% cases, 6 7% controls). At 20 years of follow up, 195 cases (88-6%) and 295 controls (70-1%) were no longer alive (X2= 26-2 on 1 df P<0-001). The median age at death for cases was 77-6 (range 53 8-97-3) years and 83-5 years (range 55 0-100 1) for controls (Wilcoxon Z = -67 P < 0001). Table 2 presents the causes of death for cases and controls with men and women shown separately. The single largest category of deaths was due to IHD for both cases and controls. Cases were more likely to have a death in the "other" diseases category as this Figure 1 shows the survival function for cases and controls stratified by sex. The median survival from entry into the study was 7-6 (95% CI 5 5-9-7) years for male cases compared with 14-1 years (95% CI 12-7-17-2) for male controls. For female cases this was 8-6 (95% CI 6 9-10-2) years compared with 15 with general population controls. Like any cohort study with a long follow up period, however, our results may be "out of date" as they reflect the experience of cases recruited in the early 1970s. As levodopa treatment was generally introduced in the early 1970s, it is likely that most of these cases would have received levodopa medication, but this may have been at an advanced stage in the natural history of their disease. It is also important to consider possible errors in diagnosis and how they might have affected our results. Two prevalence studies from the United Kingdom provide estimates as to the possible proportion of ascertained cases that were either drug induced (3 9%, 1811%) or had another condition-for example, benign essential tremor (8-5%, 14.5%). 24 25 Assuming that subjects with benign essential tremor have no increased mortality, the inclusion of some subjects with drug induced Parkinson's disease would bias our results towards increased mortality. Most studies indicate that those with schizophrenia have around twice the mortality risk compared with the general population.26 27 This is more pronounced in young schizophrenic patients,'7 and should introduce less bias in this sample. Clinicopathological studies also highlight the difficulties of making an accurate diagnosis of idiopathic Parkinson's disease28 and it is likely that some cases of atypical parkinsonism with a worse prognosis were included. Mild parkinsonian cases may also have been underascertained as they could have been less likely to have seen their general practitioner in the study year. For all of these reasons, our estimate of relative mortality may be overly pessimistic.
Doubt still remains over whether the introduction of levodopa has reduced mortality. Some studies have shown little difference in mortality for parkinsonian cases, since drug treatment (see table 1).57 8 Two of these studies were limited to only three years of follow up. With further follow up, the difference in relative mortality has been seen to increase."3 A recent analysis from the Olmsted County Project does suggest that patients treated with levodopa have improved survival, especially in the first five years.'4 Their multivariate analysis attempted to control for selection bias, which is an inherent problem with retrospective observational studies. Their results, however, may still reflect the effects of residual confounding due to measurement error in the confounding variables.29 Two other studies have also noted, like ours, a greater than twofold increase in mortality.'3 16 This includes a recent cohort (1984) of cases of Parkinson's disease recruited from a prevalence study in Aberdeen.'4 Only 8% of these cases had not received levodopa medication.'6 Despite more than 10 years between this and our study, the estimates of relative mortality are remarkably similar (2-6 v 2.4).16 DO 2) . Neither of the two population based cohorts find any sex difference, supporting the idea that the worse survival seen in some studies may be due to the recruitment of more severely disabled women. Similarly the Olmsted County Project found no sex difference in mortality relative to the normal population'4 (not shown as the data are not given).
CAUSE OF DEATH
Previous research has only compared total mortality for parkinsonian cases with the general population. Data on the proportion of deaths from specific causes are available,4731 but not as cause specific mortality. This is potentially misleading as it is dependent on the relative number of deaths from a specific cause compared with other causes. For example, if the risk of dying from IHD was identical for patients with Parkinson's disease and the general population, mortality from IHD would be identical but the proportion of deaths from IHD to total deaths would seem less as patients with Parkinson's disease are more likely to die of other causes such as bronchopneumonia than controls. This problem is also found when interpreting proportional mortality ratios. Also, because we have follow up data, it is possible to calculate the mortality rate rather than simply the cumulative mortality risk. To illustrate this distinction, imagine that all cases and controls are followed up until death. The proportion of deaths for both groups is identical and the risk ratio is unity. However, if cases are dying at a faster rate than controls, the hazard ratio will be increased.
Studies have suggested that cancer is less common among parkinsonian cases.43' 3' This is not surprising as smoking is less common among patients with Parkinson's disease" 33 and therefore the risk of smoking related cancers should be reduced. Our results support this but do not show any difference in the mortality risk for cancers not related to smoking. We believe that lower total cancer mortality is a consequence of smoking behaviour. Respiratory disease, in particular pneumonia but excluding chronic obstructive airways disease, was also more common as a cause of death. This has been noted before34 and two possible suggestions for this include central autonomic dysfunction and an effect of med-ication on respiratory behaviour. The increase in respiratory deaths is also seen with Alzheimer's disease,35 another neurodegenerative disorder, and may reflect a non-specific artifact due to certification behaviour. Only around a third of death certificates that record respiratory disease as the cause of death are validated by necropsy.36 This figure is far lower than that for neoplasms (85%) and ischaemic heart disease 3 6 (75%).3
As IHD is also linked to smoking,9 we expected this too to be less common. Surprisingly, the cases had a significantly greater risk of dying from IHD. Previous casecontrol studies have failed to note any increase in cardiovascular disease.37 73 These studies simply used self reported histories, however, and not standard methods of ascertaining ischaemic heart disease. One retrospective cohort study noted fewer reports of cardiovascular or cerebrovascular disease for a group of parkinsonian cases than for a hospital group of patients with skin cancer.40 Only non-fatal events were recorded, however, by examining the hospital notes of patients attending clinics or seen as inpatients. Furthermore, only the number of events rather than the rate of events was examined.
The increased mortality from IHD is unlikely to be a certification artifact as the IHD false positive rate on death certificates is only 25%. 36 We do not believe that this would be systematically biased, so that a case with pre-existing parkinsonism is no more likely to have IHD stated as cause of death than a control. Also, IHD is the most common cause of death, even in non-smokers.23 As parkinsonian cases are less likely to die of smoking related diseases because of their smoking behaviour, then they will have to die of another common cause, such as IHD ("competing cause hypothesis"). We do not believe that this explanation is sufficient to explain our findings as even when we compared an extreme scenario by combining death from IHD, smoking related cancers, and chronic obstructive airways disease, the cases still had a greater risk of dying. It has recently been suggested that the inverse association between smoking, Alzheimer's disease, and Parkinson's disease may reflect the differential survival between smokers and non-smokers. 
